Madrigal Pharmaceuticals (MDGL) stock is drawing attention after partner Suzhou Ribo Life Science reported the first candidate drug nomination in its siRNA program targeting liver diseases, including metabolic dysfunction associated steatohepatitis, or MASH.

The latest siRNA milestone arrives after a period of index reshuffling for Madrigal Pharmaceuticals, with the stock moving into larger Russell benchmarks and posting a 1 month share price return of 11.99% alongside a 1 year total shareholder return of 89.68%. This points to momentum that has cooled year to date but remains strong over longer horizons.

If this kind of liver disease progress has your attention, it can be worth scanning for other healthcare names benefiting from AI and data driven drug development. You can start with our screener of 40 healthcare AI stocks

Bulls point to Madrigal Pharmaceuticals’ MASH focus, fresh siRNA progress and index upgrades, while bears see losses, a rich share price and execution risk. Which side does the current valuation lean toward as investors weigh the stock’s next phase?

Most Popular Narrative: 19.6% Undervalued

Compared with Madrigal Pharmaceuticals' last close at $545.36, the most widely followed narrative pegs fair value at $678.71, highlighting a sizable valuation gap investors are actively debating.

The rapid uptake and long-term patent protection of Rezdiffra, supported by a new U.S. patent that extends exclusivity to 2045, provides decades of protected revenue opportunity; this increases the likelihood of sustained top-line growth and supports margin expansion due to extended pricing power.

Read the complete narrative. Read the complete narrative.

Want to see what kind of revenue curve and profit swing that level of pricing power implies? The narrative builds a detailed path from current losses to sizeable earnings and a higher future earnings multiple, all distilled into that single fair value figure.

Result: Fair Value of $678.71 (UNDERVALUED)

However, Madrigal Pharmaceuticals still faces meaningful risks, including its heavy reliance on Rezdiffra and the possibility that competition or reimbursement hurdles could limit the bullish narrative.

Next Steps

With Madrigal Pharmaceuticals framed as both an opportunity and a risk, it makes sense to move quickly, check the underlying data, and test the bullish case against your own expectations by reviewing the 3 key rewards

Looking for more investment ideas beyond Madrigal Pharmaceuticals?

If you are serious about building a stronger portfolio, do not stop at Madrigal Pharmaceuticals. Use these focused stock ideas to pressure test and upgrade your watchlist.

• Target potential mispricings by scanning our list of 45 high quality undervalued stocks that combine quality fundamentals with attractive valuations.
• Strengthen your income stream by reviewing 9 dividend fortresses that aim for higher yields with robust payout profiles.
• Protect your capital by checking out 74 resilient stocks with low risk scores designed to prioritize resilience and lower overall risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.